

ENANTA PHARMACEUTICALS INC  
 Form 4  
 February 20, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Golumbeski George

2. Issuer Name and Ticker or Trading Symbol  
 ENANTA PHARMACEUTICALS INC [ENTA]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 02/19/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

WATERTOWN, MA 02471

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Title and Amount of Underlying Securities (Instr. 3 and 4)
Stock Option (right to bury)	\$ 33.65	02/19/2015		A	6,000	(1) 02/19/2025	Common Stock	6,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Golumbeski George C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN, MA 02471	X			

## Signatures

/s/ Nathaniel S. Gardiner, as attorney-in-fact  
Date: 02/19/2015

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 19, 2015), with the final monthly installment vesting at the 2016 annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. Opt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">**SCHEME (2000)**

**ALLERGAN, INC. 1989 NONEMPLOYEE DIRECTOR STOCK PLAN**

**ALLERGAN, INC. EXECUTIVE DEFERRED COMPENSATION PLAN**

**ALLERGAN, INC. DEFERRED DIRECTORS FEE PROGRAM**

**ALLERGAN, INC. STOCK PRICE INCENTIVE PLAN**

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4  
**ALLERGAN, INC. 1989 INCENTIVE COMPENSATION PLAN**  
**ALLERGAN, INC. SAVINGS AND INVESTMENT PLAN**

**EMPLOYEE RECOGNITION AWARD PLAN**  
**1989 INCENTIVE COMPENSATION PLAN**  
**SAVINGS AND INVESTMENT PLAN**  
**1989 NONEMPLOYEE DIRECTOR STOCK PLAN**  
**(Full Title of the Plans)**

**A. Robert D. Bailey**  
**Chief Legal Officer and Corporate Secretary**

**Actavis plc**  
**Morris Corporate Center III**  
**400 Interpace Parkway**  
**Parsippany, New Jersey 07054**  
**(862) 261-7000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>

(Do not check if a smaller reporting company)

### DEREGISTRATION OF SECURITIES

Allergan, Inc. (the Registrant ), is filing this Post-Effective Amendment to each of the following Registration Statements on Form S-8 (collectively, the Registration Statements ) to deregister any and all securities that remain unsold under such Registration Statements.

- (1) Registration Statement No. 333-193149, filed with the Securities Exchange Commission (the Commission ) on December 31, 2013, registering the offer and sale of 150,000 shares of the Registrant's common stock, par value \$0.01 per share (the Common Stock ), issuable pursuant to the Registrant's Allergan Irish Share Participation Scheme;
- (2) Registration Statement No. 333-174025, filed with the Commission on May 6, 2011, registering the offer and sale of 21,821,946 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2011 Incentive Award Plan;
- (3) Registration Statement No. 333-158925, filed with the Commission on April 30, 2009, registering the offer and sale of 2,500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan (Restated 2008), as amended;
- (4) Registration Statement No. 333-150668, filed with the Commission on May 6, 2008, registering the offer and sale of 22,500,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2008 Incentive Award Plan;
- (5) Registration Statement No. 333-133817, filed with the Commission on May 4, 2006, registering the offer and sale of 350,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2003 Nonemployee Director Equity Incentive Plan;
- (6) Registration Statement No. 333-117939, filed with the Commission on August 4, 2004, registering \$65,000,000 in deferred compensation obligations of the Registrant pursuant to the Registrant's Executive Deferred Compensation Plan (Amended and Restated as of January 1, 2003), as amended;
- (7) Registration Statement No. 333-117937, filed with the Commission on August 4, 2004, registering the offer and sale of 500,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's Savings and Investment Plan (Restated 2003), as amended;
- (8) Registration Statement No. 333-117936, filed with the Commission on August 4, 2004, registering the offer and sale of 250,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2003 Nonemployee Director Equity Incentive Plan;
- (9)

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 4

Registration Statement No. 333-117935, filed with the Commission on August 4, 2004, registering the offer and sale of 16,000,000 shares of the Registrant s

Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan, as amended;

- (10) Registration Statement No. 333-65176, filed with the Commission on July 16, 2001, registering the offer and sale of 2,400,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's 2001 Premium Priced Stock Option Plan;
- (11) Registration Statement No. 333-43584, filed with the Commission on August 11, 2000, registering the offer and sale of 300,000 shares of the Registrant's Common Stock issuable pursuant to the Registrant's Allergan Pharmaceuticals (Ireland) Ltd., Inc. Savings Related Share Option Scheme (2000);
- (12) Registration Statement No. 333-43580, filed with the Commission on August 11, 2000, registering the offer and sale of 50,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Nonemployee Director Stock Plan;
- (13) Registration Statement No. 333-94157, filed with the Commission on January 6, 2000, registering \$12,500,000 in deferred compensation obligations of the Registrant pursuant to the Registrant's Executive Deferred Compensation Plan;
- (14) Registration Statement No. 333-94155, filed with the Commission on January 6, 2000, registering \$26,000,000 in deferred compensation obligations of the Registrant pursuant to the Registrant's Deferred Directors' Fee Program, as well as the offer and sale of 500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Deferred Directors' Fee Program;
- (15) Registration Statement No. 333-70407, filed with the Commission on January 11, 1999, registering the offer and sale of 18,431 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Stock Price Incentive Plan;
- (16) Registration Statement No. 333-64559, filed with the Commission on September 29, 1998, registering the offer and sale of 50,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Nonemployee Director Stock Plan;
- (17) Registration Statement No. 333-25891, filed with the Commission on April 25, 1997, registering the offer and sale of 5,000,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan;
- (18) Registration Statement No. 333-09091, filed with the Commission on July 29, 1996, registering the offer and sale of 500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan;

- (19) Registration Statement No. 333-04859, filed with the Commission on May 31, 1996, registering the offer and sale of 150,000 shares of the Registrant's Common



Stock, issuable pursuant to the Registrant's Allergan Irish Share Participation Scheme;

- (20) Registration Statement No. 33-66874, filed with the Commission on August 2, 1993, registering the offer and sale of 100,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Employee Recognition Award Plan;
- (21) Registration Statement No. 33-48908, filed with the Commission on June 30, 1992, registering the offer and sale of 5,000,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan;
- (22) Registration Statement No. 33-44770, filed with the Commission on December 24, 1991, registering the offer and sale of 470,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan;
- (23) Registration Statement No. 33-29528, filed with the Commission on June 26, 1989, registering the offer and sale of 500,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's Savings and Investment Plan; and
- (24) Registration Statement No. 33-29527, filed with the Commission on June 26, 1989, registering the offer and sale of 5,050,000 shares of the Registrant's Common Stock, issuable pursuant to the Registrant's 1989 Incentive Compensation Plan and 1989 Nonemployee Director Stock Plan.

On March 17, 2015, pursuant to the Agreement and Plan of Merger, dated November 16, 2014, among the Registrant, Actavis plc, an Irish public limited company (Actavis), and Avocado Acquisition Inc., a Delaware corporation and an indirect wholly owned subsidiary of Actavis (Merger Sub), Registrant merged with and into Merger Sub, with the Registrant being the surviving entity (the Merger).

In connection with the Merger, the Registrant has terminated all offers and sales of its securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Registrant to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offerings, the Registrant hereby removes from registration any and all securities registered but unsold under the Registration Statements as of the date hereof.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Parsippany, State of New Jersey on the 17th day of March 2015.

**ALLERGAN, INC.**

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ A. Robert D. Bailey A. Robert D. Bailey	President and Chairman of the Board  <i>(Principal Executive Officer)</i>	March 17, 2015
/s/ Steve Kaufhold Steve Kaufhold	Treasurer <i>(Principal Financial and Accounting Officer)</i>	March 17, 2015
/s/ Maria Teresa Hilado Maria Teresa Hilado	Director	March 17, 2015